{
    "id": 16584,
    "fullName": "NBN inact mut",
    "impact": "unknown",
    "proteinEffect": "loss of function",
    "geneVariantDescriptions": [
        {
            "description": "NBN inact mut indicates that this variant results in a loss of function of the Nbn protein. However, the specific amino acid change has not been identified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "category",
    "gene": {
        "id": 4683,
        "geneSymbol": "NBN",
        "terms": [
            "NBN",
            "AT-V1",
            "AT-V2",
            "ATV",
            "NBS",
            "NBS1",
            "P95"
        ]
    },
    "variant": "inact mut",
    "createDate": "01/15/2016",
    "updateDate": "05/15/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 17320,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Imfinzi (durvalumab) plus Lynparza (olaparib) resulted in a decrease in PSA greater than or equal to 50% in 53% (9/17) of patients with metastatic castrate-resistant prostate cancer, with one responder with an ongoing response at 12 mo harboring a deleterious mutation in the DNA damage response (DDR) gene NBN, and resulted in a 12-mo. PFS probability of 83.3% in patients with mutations in DDR genes, compared to 36.4% in patients without a DDR gene mutation (PMID: 30514390; NCT02484404).",
            "molecularProfile": {
                "id": 16862,
                "profileName": "NBN inact mut"
            },
            "therapy": {
                "id": 2894,
                "therapyName": "Durvalumab + Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15371,
                    "pubMedId": 30514390,
                    "title": "Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30514390"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20470,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II (TOPARP-B) trial, Lynparza (olaparib) treatment resulted in a composite overall response rate of 20.0% (4/20) and a RECIST objective response rate of 0% (0/17) in patients with castration-resistant prostate cancer harboring deleterious mutations in DNA damage response genes, including ARID1A, ATRX, CHEK1/2, FANCA, FANCF, FANCG, FANCI, FANCM, MSH2, NBN, RAD50, and WRN (n=1, 1, 1, 5, 5, 2, 1, 1, 2, 1, 1, 1, 7, respectively) (PMID: 31806540; NCT01682772).",
            "molecularProfile": {
                "id": 16862,
                "profileName": "NBN inact mut"
            },
            "therapy": {
                "id": 837,
                "therapyName": "Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17849,
                    "pubMedId": 31806540,
                    "title": "Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31806540"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 16862,
            "profileName": "NBN inact mut",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}